Skip to main content

Table 2 Patient’s baseline clinical characteristics, N = 105

From: Dipeptidyl Peptidase-4 inhibitors use in type II diabetic patients in a tertiary hospital

Parameters/characteristicsn (%)
Duration of T2DM (years)a11.5 ± 8.5
 ≤ 1053 (50.5)
 11–2039 (37.1)
 21–308 (7.6)
 > 305 (4.8)
Comorbidities 
 Hypertension74 (70.5)
 Dyslipidaemia50 (47.6)
 Ischaemic heart disease12 (11.4)
 Cerebrovascular accident2 (1.9)
 Renal impairment13 (12.4)
 Liver impairment9 (8.6)
 Heart failure5 (4.8)
Diabetic complications 
 Neuropathy9 (8.6)
 Nephropathy5 (4.8)
 Retinopathy12 (11.4)
 All of the above2 (1.9)
HbA1c (%)a8.5 ± 1.8
 < 6.58 (7.6)
 6.5–9.976 (72.4)
 ≥ 1021 (20.0)
FBG (mmol/L)a9.1 ± 3.8
ALT (μmol/L)a31.0 ± 0.2
TC (mmol/L)a5.0 ± 4.0
TG (mmol/L)a1.9 ± 1.3
LDL (mmol/L)a2.6 ± 0.9
HDL (mmol/L)a1.2 ± 0.4
  1. aContinuous variable reported as mean ± SD